Cargando…
Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up
INTRODUCTION: The development of biomarkers to guide management of anti–tumor necrosis factor (TNF) agents in patients with inflammatory bowel disease (IBD) is an unmet need. We developed an in vitro blood assay to predict patient long-term outcome with the anti-TNFα agent infliximab (IFX). METHODS:...
Autores principales: | Bravo, Francisco, Macpherson, Jamie A., Slack, Emma, Patuto, Nicolas, Cahenzli, Julia, McCoy, Kathy D., Macpherson, Andrew J., Juillerat, Pascal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886452/ https://www.ncbi.nlm.nih.gov/pubmed/33735154 http://dx.doi.org/10.14309/ctg.0000000000000298 |
Ejemplares similares
-
CD62L (L-Selectin) Shedding for Assessment of Perioperative Immune Sensitivity in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass
por: Erdoes, Gabor, et al.
Publicado: (2013) -
Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells
por: Spadaro, Michela, et al.
Publicado: (2015) -
L-Selectin/CD62L Is a Key Driver of Non-Alcoholic Steatohepatitis in Mice and Men
por: Drescher, Hannah K., et al.
Publicado: (2020) -
The Shedding of CD62L (L-Selectin) Regulates the Acquisition of Lytic Activity in Human Tumor Reactive T Lymphocytes
por: Yang, Shicheng, et al.
Publicado: (2011) -
Structural requirements regulate endoproteolytic release of the L- selectin (CD62L) adhesion receptor from the cell surface of leukocytes
Publicado: (1995)